These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1457 related items for PubMed ID: 12506268

  • 1. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V, Cardiac Safety in Schizophrenia Group.
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [Abstract] [Full Text] [Related]

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM, avec le soutien institutionnel du laboratoire Lilly.
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Reduction of prolonged QTc-interval related risks in treatment with neuropharmacological drugs. Recommendations for clinical practice].
    van de Kraats GB, Slob J, Tenback DE.
    Tijdschr Psychiatr; 2007 Sep; 49(1):43-7. PubMed ID: 17225205
    [Abstract] [Full Text] [Related]

  • 5. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C, Canceil O, Iaria P.
    Encephale; 2000 Sep; 26(6):62-72. PubMed ID: 11217540
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
    Vieweg WV.
    J Clin Psychiatry; 2002 Sep; 63 Suppl 9():18-24. PubMed ID: 12088172
    [Abstract] [Full Text] [Related]

  • 7. Schizophrenia and sudden cardiac death: a review.
    Koponen H, Alaräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, Savolainen M, Isohanni M.
    Nord J Psychiatry; 2008 Sep; 62(5):342-5. PubMed ID: 18752109
    [Abstract] [Full Text] [Related]

  • 8. The safety of atypical antipsychotics: does QTc provide all the answers?
    Nielsen J.
    Expert Opin Drug Saf; 2011 May; 10(3):341-4. PubMed ID: 21504386
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
    Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar 17; 34(2):401-5. PubMed ID: 20079791
    [Abstract] [Full Text] [Related]

  • 11. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM, Anderson IM.
    Drugs; 2002 Mar 17; 62(11):1649-71. PubMed ID: 12109926
    [Abstract] [Full Text] [Related]

  • 12. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
    Lawrence KR, Nasraway SA.
    Pharmacotherapy; 1997 Mar 17; 17(3):531-7. PubMed ID: 9165555
    [Abstract] [Full Text] [Related]

  • 13. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
    Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK.
    Drugs Aging; 2009 Mar 17; 26(12):997-1012. PubMed ID: 19929028
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP.
    Fundam Clin Pharmacol; 2004 Apr 17; 18(2):139-51. PubMed ID: 15066127
    [Abstract] [Full Text] [Related]

  • 16. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
    Kecskeméti V.
    Neuropsychopharmacol Hung; 2004 Mar 17; 6(1):5-12. PubMed ID: 15125308
    [Abstract] [Full Text] [Related]

  • 17. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL, Kung MF.
    Pharmacoepidemiol Drug Saf; 2009 Mar 17; 18(3):235-9. PubMed ID: 19145580
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM.
    J Fam Pract; 2005 Jun 17; Suppl():S8-S14. PubMed ID: 15938993
    [Abstract] [Full Text] [Related]

  • 20. QTc prolongation, torsades de pointes, and psychotropic medications.
    Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC.
    Psychosomatics; 2013 Jun 17; 54(1):1-13. PubMed ID: 23295003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.